Offsite construction specialist Merit has increased the capacity of its advanced manufacturing facility in Cramlington by 40 per cent to 140,000 sq ft after securing more than £18m in new orders during the first quarter of 2020.
The company is targeting continued growth throughout the year with a pipeline of bids in excess of £50m currently under consideration.
The recent new business wins include a contract to deliver the third phase expansion of the Cell and Gene Therapy Catapult (CGT Catapult) manufacturing centre in Stevenage.
In response to the coronavirus crisis, Merit has adapted its designs to create products for mobile coronavirus testing laboratories, vaccine manufacturing facilities and biocontainment suites.
Managing director Tony Wells said: "The expansion of our manufacturing facility is part of our continued investment in a strategy that puts us at the forefront of innovation in construction.
"We are not constrained by traditional construction models which gives us the agility required to adapt quickly to client needs, which has allowed us to develop a range of solutions to meet the challenges of the current coronavirus crisis.
"Our design team applies new and existing technologies intelligently to create zero carbon solutions in industrial environments, helping clients address the challenges of climate change."
For more Offsite construction information and to hear the latest developments within the Offsite technology sector join our Explore Offsite LinkedIn Group
